July 23, 2014
The Hospital Disinfectant That’s Making Fracking Greener
Article originally published on Forbes.com – 7/23/14
“Integrated Environmental Technologies (IET) originally developed the solution as a final surface cleaner to eliminate hospital-acquired infections like tuberculosis, and then to prevent foodborne illnesses in food production. Excelyte has been proven to be 99.9999% effective against HIV, H1N1, Salmonella, E. coli, Listeria, among other bacteria and viruses. The solution’s main active ingredient is hypochlorous acid—a naturally occurring molecule in the human body that fights infection”
I have found you can usually believe what Rick says.
Nicotine-containing products and methods of making
US 20140261479 A1
Provided herein are nicotine-containing products that also contain anatabine. Also provided are methods of making such products.
I'd really like to know who they are planning on buying the warrants from,how many they are buying back, and at what price. Wouldn't it be less dilutive to not issue new shares and warrants and forget about the other warrants that they want to buy. Seems like potential for a sweetheart deal for the warrant owners that are about to be bought by the company. The strategy seems a bit dubious.
The closing price must also be above $1 on the last day.
802.01C Price Criteria for Capital or Common Stock
The company can regain compliance at any time during the six-month cure period if on the last trading day of any calendar month during the cure period the company has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. In the event that at the expiration of the six-month cure period, both a $1.00 closing share price on the last trading day of the cure period and a $1.00 average closing share price over the 30 trading-day period ending on the last trading day of the cure period are not attained, the Exchange will commence suspension and delisting procedures.
I usually don't agree with ocer, but you did ask him why other companies didn't have anatabine on the market. He responded that the sales of the product weren't strong enough to make it worthwhile.
caymenchem makes anatabine, although it is labeled as not fit for human consumption.
he didn't switch up the argument, you did when you asked if he had see it manufactored by somebody else. He provided a business case (lack of sales) of why there are no other makers.
caymenchem makes sells some in an ethenol solution not for human consumption. I don't know how they make it but clearly somebody other than rcpi is capable of producing anatabine.
The Bio Pharma presention is posted. Nothing really new in my book. A re-hashing of the mouse studies, and the thyroiditis study. A time line for IND filings both in the US and UK. They expect a response from the FDA in 2014.
I find the following things interesting:
1) 10mth maturity
2) interest to be paid in shares or cash at the option of the note holder
3) in the event of a default the note holders will receive common stock
4) notes shall be made in the event of a buyout or merger
My guess is the money raised is to be used to take the company to an exchange. I've read that takes $500k-$1mm bucks. I think there will be a r/s, an uplisting, (both already announced) and selling of additional shares a re-ipo if you will, all within the next 10 months.